Martha Stewart Discusses 2001 ImClone Stock Sale and FDA Influence
What happened
Martha Stewart discussed her past legal problems, noting that a stock sale she made in 2001 was influenced by an anticipated decision from the FDA. On December 27, 2001, Stewart sold her shares of ImClone Systems just before the biotechnology firm was expected to receive a rejection from the FDA regarding its experimental cancer drug, Erbitux. The SEC calculated that Stewart avoided losses of $45,673 from this transaction.
From indiatimes.com
Why it matters
The incident involved an investigation by the SEC into whether Stewart received confidential information regarding the FDA's regulatory plans. In 2004, a federal jury found Stewart guilty of conspiracy, obstruction of justice, and making false statements to investigators.
From indiatimes.com
Who's involved
- Martha StewartAmerican businesswoman who faced legal issues stemming from stock sales involving ImClone Systems.
- FDARegulatory agency whose decisions were linked to a stock sale involving Martha Stewart.
- ImClone SystemsBiotechnology firm whose drug was the subject of the FDA's anticipated decision.
Keep exploring
The entities involved
-
Martha Stewart
American businesswoman, writer, TV personality (born 1941)
Nothing else this week.
-
FDA
- TraceLink advances multinational compliance roadmaps in Egypt and Ethiopia while addressing FDA's transition to 12-digit National Drug Code.
- Hemogenyx Pharmaceuticals Plc submitted an IND application for its HG-CT-1 therapy with the FDA and is building infrastructure for early commercialization in Europe.